About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows:

  • Title: Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
    Presenter: Jolanta Skarbaliene, Ph.D.
    Format: Oral Presentation, Session II
    Date, time: Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
  • Title: Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL
    Presenter: Markus Magerl, M.D.
    Format: Oral Presentation, Session VII
    Date, time: Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Clinical Trials Conformity with AURORA COS: a systematic literature review
    Presenter: Remy Petersen, M.D., Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant
    Presenter: Nieves Crespo, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: The bradykinin challenge model translates across rat, monkey and human
    Presenter: Juan Bravo, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat
    Presenter: Anne Lesage, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: A novel kinin biomarker assay for characterization of bradykinin-mediated disorders
    Presenter: Evangelia Pardali, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders
    Presenter: Evangelia Pardali, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

Upon lift of the embargo, the presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both in the prophylactic and on-demand setting. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visit https://pharvaris.com/.


Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
maggie.beller@pharvaris.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.